By Chris Wack
IMV Inc. said it has dosed its first patient in a Phase 2B clinical trial to further evaluate the clinical benefit of its lead compound, maveropepimut-S, in combination with Merck & Co.'s Keytruda in patients with relapsed/refractory diffuse large B cell lymphoma.
The company said the contribution of low dose cyclophosphamide as an immune modulator will also be evaluated in the trial.
IMV said the study is an open label study, and it is expecting to review early data in the summer 2022.
Across the arms of this study, the combination will be evaluated in up to 150 subjects with r/r DLBCL who have received at least two prior lines of systemic therapy and who are ineligible or have failed autologous stem cell transplant or CAR-T therapy, the company said.
IMV shares were up 11% to $1.40 in premarket trading.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires